187 related articles for article (PubMed ID: 23275831)
1. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).
Pireddu R; Forinash KD; Sun NN; Martin MP; Sung SS; Alexander B; Zhu JY; Guida WC; Schönbrunn E; Sebti SM; Lawrence NJ
Medchemcomm; 2012 Jun; 3(6):699-709. PubMed ID: 23275831
[TBL] [Abstract][Full Text] [Related]
2. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Patel RA; Forinash KD; Pireddu R; Sun Y; Sun N; Martin MP; Schönbrunn E; Lawrence NJ; Sebti SM
Cancer Res; 2012 Oct; 72(19):5025-34. PubMed ID: 22846914
[TBL] [Abstract][Full Text] [Related]
3. Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.
Durley RC; Grapperhaus ML; Hickory BS; Massa MA; Wang JL; Spangler DP; Mischke DA; Parnas BL; Fobian YM; Rath NP; Honda DD; Zeng M; Connolly DT; Heuvelman DM; Witherbee BJ; Melton MA; Glenn KC; Krul ES; Smith ME; Sikorski JA
J Med Chem; 2002 Aug; 45(18):3891-904. PubMed ID: 12190312
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
5. Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.
Pan J; Yin Y; Zhao L; Feng Y
Bioorg Med Chem; 2019 Apr; 27(7):1382-1390. PubMed ID: 30819619
[TBL] [Abstract][Full Text] [Related]
6. Activation of Rho kinase isoforms in lung endothelial cells during inflammation.
Mong PY; Wang Q
J Immunol; 2009 Feb; 182(4):2385-94. PubMed ID: 19201893
[TBL] [Abstract][Full Text] [Related]
7. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe C; Bentley R; Behm DJ; Lafferty R; Stavenger R; Jung D; Bamford M; Panchal T; Grygielko E; Wright LL; Smith GK; Chen Z; Webb C; Khandekar S; Yi T; Kirkpatrick R; Dul E; Jolivette L; Marino JP; Willette R; Lee D; Hu E
J Pharmacol Exp Ther; 2007 Jan; 320(1):89-98. PubMed ID: 17018693
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.
Patel RA; Liu Y; Wang B; Li R; Sebti SM
Oncogene; 2014 Jan; 33(5):550-5. PubMed ID: 23396364
[TBL] [Abstract][Full Text] [Related]
9. Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
Shue HJ; Chen X; Schwerdt JH; Paliwal S; Blythin DJ; Lin L; Gu D; Wang C; Reichard GA; Wang H; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Nomeir AA; Morgan CA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2006 Feb; 16(4):1065-9. PubMed ID: 16290143
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
Trivedi BK; Purchase TS; Holmes A; Augelli-Szafran CE; Essenburg AD; Hamelehle KL; Stanfield RL; Bousley RF; Krause BR
J Med Chem; 1994 May; 37(11):1652-9. PubMed ID: 8201599
[TBL] [Abstract][Full Text] [Related]
11. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.
Li R; Martin MP; Liu Y; Wang B; Patel RA; Zhu JY; Sun N; Pireddu R; Lawrence NJ; Li J; Haura EB; Sung SS; Guida WC; Schonbrunn E; Sebti SM
J Med Chem; 2012 Mar; 55(5):2474-8. PubMed ID: 22272748
[TBL] [Abstract][Full Text] [Related]
13. Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells.
Ramachandran C; Patil RV; Combrink K; Sharif NA; Srinivas SP
Mol Vis; 2011; 17():1877-90. PubMed ID: 21850162
[TBL] [Abstract][Full Text] [Related]
14. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
[TBL] [Abstract][Full Text] [Related]
15. Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies.
Ghosh AK; Brindisi M; Yen YC; Lendy EK; Kovela S; Cárdenas EL; Reddy BS; Rao KV; Downs D; Huang X; Tang J; Mesecar AD
ChemMedChem; 2019 Mar; 14(5):545-560. PubMed ID: 30637955
[TBL] [Abstract][Full Text] [Related]
16. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.
Vigil D; Kim TY; Plachco A; Garton AJ; Castaldo L; Pachter JA; Dong H; Chen X; Tokar B; Campbell SL; Der CJ
Cancer Res; 2012 Oct; 72(20):5338-47. PubMed ID: 22942252
[TBL] [Abstract][Full Text] [Related]
17. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
Calò LA; Vertolli U; Pagnin E; Ravarotto V; Davis PA; Lupia M; Naso E; Maiolino G; Naso A
Life Sci; 2016 Mar; 148():80-5. PubMed ID: 26872982
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
Kast R; Schirok H; Figueroa-Pérez S; Mittendorf J; Gnoth MJ; Apeler H; Lenz J; Franz JK; Knorr A; Hütter J; Lobell M; Zimmermann K; Münter K; Augstein KH; Ehmke H; Stasch JP
Br J Pharmacol; 2007 Dec; 152(7):1070-80. PubMed ID: 17934515
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
20. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
